



**FY2022 Q3 YTD**  
Financial Results

Reported Revenue Growth

**+13.9%**

Core Revenue Growth at CER

**+4.5%**

Reported Operating Profit Change

**-13.1%**

Impacted by one-time gain on sale of Japan diabetes portfolio in FY2021 Q1

Core Operating Profit Growth at CER

**+9.7%**

Core Operating Profit Margin

**31.1%**

Reported EPS Growth

**+19.6%**

Core EPS Growth at CER

**+17.1%**

Free Cash Flow


**¥585.2<sub>B</sub>**

Net Debt / Adjusted EBITDA

Improved to

**2.5x**

# FY2022 Q3 YTD Financial Results



Gastroenterology

**¥857.5B** +11%

(28% of Total Sales)



Rare Diseases

**¥553.6B** +5%

(18% of Total Sales)



PDT Immunology

**¥502.4B** +18%

(16% of Total Sales)



Oncology

**¥345.0B** -13%

(11% of Total Sales)



Neuroscience

**¥477.1B** +10%

(16% of Total Sales)

Year-on-year sales growth rates are at CER



Our extensive portfolio of **Growth and Launch Products** is driving accelerated growth

Share of Total Revenue

**39%**

Growth at CER

**+20%**

# FY2022 Outlook

Revenue

**¥3,930B**

Core Operating Profit

**¥1,180B**

Core EPS

**¥525**

## Management Guidance at CER

Core Revenue

**Low-single-digit growth**

Core Operating Profit

**High-single-digit growth**

Core EPS

**High-single-digit growth**



Maintaining well-established  
dividend policy of

**¥180**

Per share annually

“Our third quarter performance showed sustained momentum, with our Growth & Launch Products driving strong revenue growth. We are advancing our pipeline with notable approvals in the EU and China, and our robust financial position is enabling us to further deleverage while investing for growth.”

**Costa Saroukos**

Chief Financial Officer



This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2022 Q3 investor presentation (available at [takeda.com/investors/financial-results](https://www.takeda.com/investors/financial-results)), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2022 Q3 investor presentation (available at [takeda.com/investors/financial-results](https://www.takeda.com/investors/financial-results)) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.

